Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.68 |
| ▸ | NQO2 | P16083 | 3/20 | 0.67 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037443 | 0.90 | MTNR1A (0.63) | MTNR1ANQO2MTNR1BCASP1TRPV1 | |
| SCHEMBL14615503 | 0.90 | MTNR1A (0.67) | MTNR1ANQO2MTNR1BCASP1 | |
| SCHEMBL4403373 | 0.84 | ANPEP (0.61) | MTNR1AKMT2A | |
| SCHEMBL29941181 | 0.84 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL761446 | 0.84 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL9128038 | 0.84 | MTNR1A (0.63) | MTNR1ANQO2MTNR1BCASP1KMT2A | |
| SCHEMBL1567114 | 0.82 | MTNR1A (0.73) | MTNR1ANQO2MTNR1BKMT2ATRPV1 | |
| SCHEMBL8065745 | 0.81 | MTNR1A (0.68) | MTNR1ANQO2 | |
| SCHEMBL14974026 | 0.81 | MTNR1A (0.59) | MTNR1ANQO2MTNR1B | |
| SCHEMBL9490563 | 0.81 | MTNR1A (1.00) | MTNR1ANQO2MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | MTNR1A 3955/4885NQO2 595/4885MTNR1B 3893/4885 |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | MTNR1A 908/4885NQO2 120/4885MTNR1B 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.